Mental health problems are endemic across the globe, and suicide, a strong corollary of poor mental health, is a leading cause of death. Classic psychedelic use may occasion lasting improvements in mental health, but the effects of classic psychedelic use on suicidality are unknown. We evaluated the relationships of classic psychedelic use with psychological distress and suicidality among over 190,000 USA adult respondents pooled from the last five available years of the National Survey on Drug Use and Health (2008–2012) while controlling for a range of covariates. Lifetime classic psychedelic use was associated with a significantly reduced odds of past month psychological distress (weighted odds ratio (OR)=0.81 (0.72–0.91)), past year suicidal thinking (weighted OR=0.86 (0.78–0.94)), past year suicidal planning (weighted OR=0.71 (0.54–0.94)), and past year suicide attempt (weighted OR=0.64 (0.46–0.89)), whereas lifetime illicit use of other drugs was largely associated with an increased likelihood of these outcomes. These findings indicate that classic psychedelics may hold promise in the prevention of suicide, supporting the view that classic psychedelics’ most highly restricted legal status should be reconsidered to facilitate scientific study, and suggesting that more extensive clinical research with classic psychedelics is warranted.
American Psychiatric Association (1994) Diagnostic and statistical manual of mental health disorders. 4th ed.Washington, DC: American Psychiatric Association
.
2.
BaumeisterDBarnesGGiaroliG. (2014) Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. Ther Adv Psychopharmacol4: 156–169.
3.
BhagwagarZHinzRTaylorM. (2006) Increased 5-HT2A receptor binding in euthymic, medication-free patients recovered from depression: A positron emission study with [11C] MDL 100,907. Am J Psychiatry163: 1580–1587.
4.
BlackCMillerJM (in press) Meta-analysis of cytokines and chemokines in suicidality: Distinguishing suicidal versus non-suicidal patients. Biol Psychiatry. doi: 10.1016/j.biopsych.2014.10.014 Available online 30October2014
5.
BogenschutzMPPommyJM (2012) Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: From indirect evidence to testable hypotheses. Drug Test Anal4: 543–555.
6.
BorgesGWaltersEEKesslerRC (2000) Associations of substance use, abuse, and dependence with subsequent suicidal behavior. Am J Epidemiol151: 781–789.
7.
BrittonPCConnerKR (2010) Suicide attempts within 12 months of treatment for substance use disorders. Suicide Life Threat Behav40:14–21.
8.
CarballoJJAkamnonuCPOquendoMA (2008) Neurobiology of suicidal behavior. An integration of biological and clinical findings. Arch Suicide Res12: 93–110.
9.
Carhart-HarrisRLErritzoeDWilliamsT. (2012b) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A109: 2138–2143.
10.
Carhart-HarrisRLLeechRWilliamsTM. (2012a) Implications for psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin. Br J Psychiatry200: 238–244.
11.
Carhart-HarrisRLLeechRHellyerPJ. (2014) The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci8: 20.
12.
Center for Substance Abuse Treatment (2008) Substance abuse and suicide prevention: Evidence and implications—A white paper. DHHHS Pub. No. SMA-08–4352. Rockville, MD: Substance Abuse and Mental Health Services Administration.
13.
DwivediY (2010) Brain-derived neurotrophic factor and suicide pathogenesis. Ann Med42: 87–96.
14.
DwivediYRizaviHSConleyRR. (2003). Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry60: 804–815.
15.
GasserPHolsteinDMichelY. (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis202: 513–520.
16.
GasserPKirchnerKPassieT (in press) LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. J Psychopharmacol29: 57–68.
GriffithsRRRichardsWAJohnsonMW. (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol22: 621–632.
19.
GriffithsRRRichardsWAMcCannU. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology187: 268–283.
20.
GrobCSDanforthALChopraGS. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry68: 71–78.
HendricksPSClarkCBJohnsonMW. (2014) Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. J Psychopharmacol28: 62–66.
23.
JohnsonMWGarcia-RomeuACosimanoMP. (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol28: 983–992.
24.
JohnsonMWRichardsWAGriffithsRR (2008) Human hallucinogen research: Guidelines for safety. J Psychopharmacol22: 603–620.
25.
KashdanTBRosePFinchamFD (2004) Curiosity and exploration: Facilitating positive subjective experiences and personal growth opportunities. J Pers Assess82: 291–305.
26.
KelleyKClarkBBrownV. (2003). Good practice in the conduct and reporting of survey research. Int J Qual Health Care15: 261–266.
27.
KesslerRCAndrewsGColpeLJ. (2002) Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med32: 959–976.
28.
KesslerRCGreenJGGruberMJ. (2010) Screening for serious mental illness in the general population with the K6 screening scale: Results from the WHO World Mental Health (WMH) survey initiative. Int J Methods Psychiatr Res19: 4–22.
29.
KhanAChienCWBurtonNW (2014) A new look at the construct validity of the K6 using Rasch analysis. Int J Methods Psychiatr Res23: 1–8.
30.
KraehenmannRPrellerKHScheideggerM. (in press) Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry. doi:10.1016/j.biopsych.2014.04.010 Available online 26April2014
31.
KrebsTSJohansenPØ (2012) Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. J Psychopharmacol26: 994–1002.
32.
KrebsTSJohansenPØ (2013) Psychedelics and mental health: A population study. PLoS One8: e63972.
33.
LernerMLyversM (2006) Values and beliefs of psychedelic drug users: A cross-cultural study. J Psychoactive Drugs38: 143–147.
34.
LyversMMeesterM (2012) Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner. J Psychoactive Drugs44: 410–417.
35.
MacLeanKAJohnsonMWGriffithsRR (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol25: 1453–1461.
36.
MeyerJHMcMainSKennedySH. (2003) Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry160: 90–99.
37.
MóróLSimonKBárdI. (2011) Voice of the psychonauts: Coping, life purpose, and spirituality in psychedelic drug users. J Psychoactive Drugs43: 188–198.
38.
MuthukumaraswamySDCarhart-HarrisRLMoranRJ. (2013) Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci33: 15171–15183.
39.
National Action Alliance for Suicide Prevention: Research Prioritization Task Force (2014) A prioritized research agenda for suicide prevention: An action plan to save lives. National Institute of Mental Health and the Research Prioritization Task Force, Rockville, Maryland.
NuttDJKingLANicholsDE (2013) Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature Rev Neurosci14: 577–585.
42.
NuttDJKingLAPhillipsLD (2010) Drug harms in the UK: A multicriteria decision analysis. Lancet376: 1558–1565.
43.
NuttDKingLASaulsburyW. (2007) Development of a rational scale to assess the harm of drugs of potential misuse. Lancet369: 1047–1053.
44.
RasicDTBelikSLEliasB. (2009) Spirituality, religion and suicidal behavior in a nationally representative sample. J Affect Disord114: 32–40.
45.
RasicDRobinsonJABoltonJ. (2011) Longitudinal relationships of religious worship attendance and spirituality with major depression, anxiety disorders, and suicidal ideation and attempts: Findings from the Baltimore epidemiologic catchment area study. J Psychiatr Res45: 848–854.
46.
RosemanLLeechRFeildingA. (2014) The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Front Hum Neurosci8: 204.
47.
SegalDLMartyMAMeyerWJ. (2012) Personality, suicidal ideation, and reasons for living among older adults. J Gerontol B Psychol Sci Soc Sci67: 159–166.
48.
SheltonRCSanders-BushEManierDH. (2009). Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience158: 1406–1415.
49.
SzaboAKovacsAFrecskaE. (2014) Psychedelic N, N-dimethyltryptamine and 5-methoxy-N, N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells. PLoS One9: e106533.
50.
TagliazucchiECarhart-HarrisRLeechR. (2014) Enhanced repertoire of brain dynamical states during the psychedelic experience. Human Brain Mapp35: 5442–5456.
51.
United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality (2009) National Survey on Drug Use and Health, 2008. Ann Arbor, MI: Inter-university Consortium for Political and Social Research.
52.
United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality (2010) National Survey on Drug Use and Health, 2009. Ann Arbor, MI: Inter-university Consortium for Political and Social Research.
53.
United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality (2011) National Survey on Drug Use and Health, 2010. Ann Arbor, MI: Inter-university Consortium for Political and Social Research.
54.
United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality (2012) National Survey on Drug Use and Health, 2011. Ann Arbor, MI: Inter-university Consortium for Political and Social Research.
55.
United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality (2013) National Survey on Drug Use and Health, 2012. Ann Arbor, MI: Inter-university Consortium for Political and Social Research.
56.
VarnikP (2012) Suicide in the world. Int J Environ Res Public Health9: 760–771.
57.
VollenweiderFXKometerM (2010) The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nature Rev Neurosci11: 642–651.
58.
WeberSRPargamentKI (2014) The role of religion and spirituality in mental health. Curr Opin Psychiatry27: 358–363.
59.
Whitfield-GabrieliSFordJM (2012) Default mode network activity and connectivity in psychopathology. Annu Rev Clin Psychol8: 49–76.
60.
WilcoxHCConnerKRCaineED (2004) Association of alcohol and drug use disorders and completed suicide: An empirical review of cohort studies. Drug Alcohol Depend76: S11–S19.
61.
World Health Organization (2001) The World health report 2001: Mental health: New understanding, new hope. Geneva, Switzerland: World Health Organization.
